[Rituximab in patients with rheumatoid arthritis:systematic review and economic evaluation]
Brodszky V, Pentek M, Majer I, Karpati K, Gulacsi L
Record ID 32007000033
Hungarian
Authors' results and conclusions:
RTX is an effective treatment for RA compared to placebo in terms of improving symptoms and preventing radiological damage. RTX is the only agent in this indication approved by FDA and EMEA so far.
Authors' recommendations:
Rituximab can improve the symptoms of RA: Scientific evidence suggests that RTX can improve the symptoms of 51% of the patients and can lead to a five folds probability to improve health status compared to placebo.
Further study and surveillance are warranted. Outcome and harm from therapy and disease, based on scientific evidence identified, was not measured beyond one year. Funders should consider the value of prospectively measuring the costs and impact of therapy on the general population.
Details
Project Status:
Completed
Year Published:
2006
URL for published report:
http://hecon.uni-corvinus.hu/download/publik_2/rituximab.hta.2006_2.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Hungary
MeSH Terms
- Antibodies, Monoclonal
- Antirheumatic Agents
- Arthritis, Rheumatoid
Contact
Organisation Name:
Unit of Health Economics and Technology Assessment in Health Care
Contact Address:
Unit of Health Economics and Technology Assessment in Health Care Department of Public Policy and Management Budapest University of Economic Studies 1125 Budapest Fovam ter 8 Budapest HUNGARY Tel: +36 1 218 8197 Fax: +36 1 218 1466
Contact Name:
laszlo.gulacsi@uni-corvinus.hu
Contact Email:
laszlo.gulacsi@uni-corvinus.hu
Copyright:
Unit of Health Economics and Technology Assessment in Health Care (HUNHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.